Skip to main content

Table 5 Comparisons of baseline/post/change between good vs poor response in Cohort B

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Response

Good Response

Poor Response

Difference (Good - Poor)

Timepoints

Baseline

Post-treatment

Change (Post - Pre)

Baseline

Post-treatment

Change (Post - Pre)

Baseline

Post-treatment

Change

Blood biomarker

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SE)

P-value$

Mean (±SE)

P-value$

Mean (±SE)

P-value$

WBC (×103 cells/μL)

7.1 (±2.5)

6.9 (±1.9)

−0.3 (±2.1)

8.0 (±2.4)

7.4 (±3.0)

−0.6 (±3.3)

−0.8 (±0.8)

0.329

−0.5 (±0.8)

0.756

0.3 (±0.9)

0.682

Hemoglobulin (gram/dL)

13.0 (±1.4)

12.6 (±1.3)

−0.4 (±1.5)

12.4 (±2.4)

11.7 (±1.6)

−0.7 (±2.8)

0.6 (±0.6)

0.388

0.9 (±0.5)

0.138

0.3 (±0.8)

0.434

Platelet count (×103 cells/μL)

278.2 (±98.3)

278.0 (±118.1)

−0.2 (±68.1)

300.0 (±152.1)

260.1 (±160.2)

−39.9 (±105.8)

−21.8 (±43.0)

0.961

17.9 (±47.4)

0.379

39.7 (±29.9)

0.321

ANC (×103 cells/μL)

5.2 (±2.3)

4.5 (±1.7)

−0.7 (±2.1)

6.0 (±1.9)

5.4 (±2.3)

−0.6 (±2.7)

−0.7 (±0.7)

0.249

−0.9 (±0.7)

0.230

−0.1 (±0.8)

0.844

ALCs (×103 cells/μL)

1.1 (±0.6)

1.3 (±0.8)

0.3 (±0.4)

1.1 (±0.5)

0.8 (±0.3)

−0.3 (±0.3)

−0.1 (±0.2)

0.523

0.5 (±0.2)

0.032

0.6 (±0.1)

< 0.001

CD3 + CD4 + %

48.8 (±12.6)

47.2 (±13.1)

−1.6 (±8.3)

41.6 (±11.9)

39.1 (±14.0)

−2.5 (±5.6)

7.2 (±4.2)

0.083

8.1 (±4.6)

0.111

0.9 (±2.4)

0.211

CD3 + CD8 + %

23.3 (±10.4)

25.4 (±12.6)

2.1 (±7.3)

31.0 (±13.5)

32.0 (±15.7)

−1.0 (±8.0)

−7.7 (±4.1)

0.098

−6.6 (±4.8)

0.200

1.1 (±2.6)

0.534

CD3 + %

72.0 (±7.8)

72.6 (±9.3)

0.6 (±8.1)

72.8 (±12.6)

71.5 (±13.4)

−1.3 (±5.3)

−0.8 (±3.5)

0.806

1.1 (±3.9)

0.961

1.8 (±2.3)

0.150

CD3 + CD4+ count (cells/μL)

502.9 (±284.4)

593.4 (±297.3)

90.6 (±136.1)

481.1 (±300.4)

310.8 (±204.2)

−170.2 (±209.4)

21.8 (±98.8)

0.831

282.6 (±86.7)

0.008

260.8 (±59.3)

< 0.001

CD3 + CD8+ count (cells/μL)

279.5 (±322.5)

400.1 (±476.1)

120.6 (±191.6)

333.1 (±178.1)

215.2 (±106.2)

− 117.9 (±153.2)

−53.6 (±88.8)

0.060

184.9 (±118.2)

0.321

238.5 (±58.9)

< 0.001

CD4/CD8 ratio

2.6 (±1.3)

2.4 (±1.3)

−0.2 (±0.9)

1.6 (±1.2)

1.7 (±1.2)

0.0 (±0.7)

1.0 (±0.4)

0.033

0.7 (±0.4)

0.089

−0.2 (±0.3)

0.922

CD4 plus CD8 count (cells/μL)

782.4 (±482.8)

993.6 (±627.4)

211.2 (±268.1)

814.2 (±384.3)

526.1 (±251.2)

−288.1 (±329.2)

−31.8 (±148.1)

0.567

467.5 (±163.4)

0.011

499.3 (±101.2)

< 0.001

dNLR

3.1 (±1.7)

2.4 (±1.8)

−0.7 (±1.6)

3.4 (±1.3)

3.9 (±2.7)

0.6 (±2.5)

−0.2 (±0.5)

0.590

−1.5 (±0.8)

0.030

−1.3 (±0.7)

0.160

  1. $P-values from Wilcoxon rank sum tests. Bold for statistical significance
  2. Abbreviation: SD Standard Deviation, SE Standard Error
Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us